What the HIV Community Thinks About when to Start--and Start (Perspectives) (Antiretroviral Therapy) (Report)
Research Initiative/Treatment Action! 2008, Fall, 13, 2
Research Initiative/Treatment Action!
This book is available for download with iBooks on your Mac or iOS device, and with iTunes on your computer. Books can be read with iBooks on your Mac or iOS device.
The question of when antiretroviral therapy (ART) should ideally be started has been a flash-point for controversy ever since the first anti-retroviral drug, zidovudine (Retrovir, AZT), won approval in 1987. That question has recently come to the fore once again because of accumulating data-particularly from the large SMART treatment interruption trial (1)--showing that people with HIV infection face health risks that fall outside the historical definition of AIDS-related clinical events. These data have informed the design of the new START trial by the INSIGHT clinical trials network. START aims to assess the impact of earlier ART not only on AIDS-defining diseases, but also on cardiovascular, liver, and kidney disease and mortality from any cause. Burning the bulb early?
- Category: Health & Fitness
- Published: Sep 22, 2008
- Publisher: The Center for AIDS: Hope & Remembrance Project
- Seller: The Gale Group, Inc.
- Print Length: 9 Pages
- Language: English